119 related articles for article (PubMed ID: 27906842)
1. Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study.
Chuang YW; Yu MC; Huang ST; Yang CK; Chen CH; Lo YC; Lin CL; Shu KH; Yu TM; Kao CH
J Hypertens; 2017 Jan; 35(1):170-177. PubMed ID: 27906842
[TBL] [Abstract][Full Text] [Related]
2. Does spironolactone reduce the risk of urinary tract cancers in hypertensive patients?
Teo KK
J Hypertens; 2017 Jan; 35(1):36-38. PubMed ID: 27902627
[No Abstract] [Full Text] [Related]
3. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
Kim HY; Bae EH; Ma SK; Kim SW
Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A
J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595
[TBL] [Abstract][Full Text] [Related]
5. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
6. Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?
Plouin PF; Battaglia C; Alhenc-Gélas F; Corvol P
Am J Hypertens; 1991 Apr; 4(4 Pt 1):356-62. PubMed ID: 2059395
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
8. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
9. [The use of aldosterone antagonists in the cardiovascular diseases].
Trzaska E; Gumułka W; Makulska-Nowak HE
Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325
[No Abstract] [Full Text] [Related]
10. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Azizi M; Perdrix L; Bobrie G; Frank M; Chatellier G; Ménard J; Plouin PF
J Hypertens; 2014 Oct; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
Sato A; Saruta T; Funder JW
Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
[TBL] [Abstract][Full Text] [Related]
12. Additional drug treatment in resistant hypertension: need for randomized studies.
Mancia G
J Hypertens; 2012 Aug; 30(8):1514-5. PubMed ID: 22785232
[No Abstract] [Full Text] [Related]
13. Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study.
Beckmann K; Garmo H; Lindahl B; Holmberg L; Stattin P; Adolfsson J; Cruickshank JK; Van Hemelrijck M
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):527-533. PubMed ID: 32123316
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
15. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.
Gromotowicz-Poplawska A; Stankiewicz A; Mikita J; Aleksiejczuk M; Marcinczyk N; Szemraj J; Chabielska E
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980144
[TBL] [Abstract][Full Text] [Related]
18. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Kidney Int; 2007 Nov; 72(9):1164-5. PubMed ID: 17943159
[No Abstract] [Full Text] [Related]
19. Manipulation of the renin-angiotensin system.
Givertz MM
Circulation; 2001 Jul; 104(5):E14-8. PubMed ID: 11479264
[No Abstract] [Full Text] [Related]
20. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
